🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Ningbo Medical Center Lihuili Hospital clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Ningbo Medical Center Lihuili Hospital as lead sponsor. Synced 27 Sep 2026
10Current trials
7Recruiting now
3Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Ningbo Medical Center Lihuili Hospital is the lead sponsor of 10 current clinical trials in our China register. 7 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Adebrelimab, Anlotinib and Fruquintinib. The most-studied condition is Pancreatic Cancer.

ClinicalTrials.gov trials by status

  • Recruiting770%
  • Not yet open220%
  • Active, closed110%

Trials by phase

  • Not applicable660%
  • Observational330%
  • Phase 2110%
01

Clinical trials sponsored by Ningbo Medical Center Lihuili Hospital

10 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors:A Prospective Exploratory Study
NCT07542002 · ClinicalTrials.gov ↗ · Pancreatic Cancer
Phase 2 Recruiting 2025-03 China
Detection of Sepsis Occurrence by Using Blood Fluorescence
NCT06689189 · ClinicalTrials.gov ↗ · Sepsis, Organ Damage
Observational Recruiting 2024-01 China
The Effectiveness and Safety of Combined Research on Uremic Sarcopenia
NCT07724587 · ClinicalTrials.gov ↗ · Sarcopenia
Not applicable Recruiting 2025-09 China
The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study
NCT06188650 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer
Not applicable Recruiting 2023-12 China
Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer.
NCT06613113 · ClinicalTrials.gov ↗ · MSS Metastatic Colorectal Cancer
Not applicable Recruiting 2024-08 China
Efficacy of Individualized Aerobic Exercise Training in Patients With Inflammatory Bowel Disease
NCT06804733 · ClinicalTrials.gov ↗ · Inflammatory Bowel Disease (IBD)
Not applicable Recruiting 2025-05 China
Fecal Microbiota Transplantation for Liver Failure
NCT05170971 · ClinicalTrials.gov ↗ · Liver Failure
Not applicable Recruiting 2021-05 China
A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma
NCT07368023 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable
Observational Not yet open 2026-01 China
Transcutaneous Electrical Acustimulation (TEA) for the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)
NCT07572708 · ClinicalTrials.gov ↗ · Non-erosive Reflux Disease (NERD)
Not applicable Not yet open 2026-05 China
Application of in Vivo Splitting Technique in Adult Liver Transplantation
NCT06925828 · ClinicalTrials.gov ↗ · Liver Transplantation
Observational Active, closed 2021-01 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Ningbo Medical Center Lihuili Hospital trials

3 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Ningbo Medical Center Lihuili Hospital trials

12 conditions
Pancreatic Cancer1Sepsis1Organ Damage1Hepatocellular Carcinoma1Hepatocellular Carcinoma Non-resectable1Sarcopenia1Non-Small Cell Lung Cancer1MSS Metastatic Colorectal Cancer1Non-erosive Reflux Disease (NERD)1Inflammatory Bowel Disease (IBD)1Liver Failure1Liver Transplantation1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China107

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Pancreatic Cancer

SponsorTrials
Fudan University14
Changhai Hospital9
Ruijin Hospital7
Tianjin Medical University Cancer Institute and Hospital7
Peking Union Medical College Hospital7
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology6
Revolution Medicines5
IRCCS San Raffaele5
Alpha Tau Medical5
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School4

Sponsors with the most current trials registered for this condition.

06

Questions about Ningbo Medical Center Lihuili Hospital trials

How many clinical trials does Ningbo Medical Center Lihuili Hospital sponsor?

Ningbo Medical Center Lihuili Hospital is the lead sponsor of 10 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.

Are Ningbo Medical Center Lihuili Hospital trials recruiting?

Yes. 7 of its 10 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Ningbo Medical Center Lihuili Hospital testing?

Its current trials name 3 drugs and biologicals as interventions. The most frequent are Adebrelimab (1), Anlotinib (1) and Fruquintinib (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.